Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure

Hofman-Bang, Claes; Rehnqvist, Nina; Swedberg, Karl; Wiklund, Ingela; Åström, Hans

doi:10.1016/1071-9164(95)90011-x

Cited by 150 publications

(108 citation statements)

References 14 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Several human studies have suggested that CoQ supplementation ameliorated mitochondria-related abnormalities (Bresolin et al 1990;Morisco et al 1993;Hofman-Bang et al 1995) and age-related symptoms of heart failure and hypertension as well as neurodegenerative diseases including amyotrophic lateral sclerosis, Huntington's disease, and diabetic neuropathy (Baggio et al 1993;Beal et al 1994;Koroshetz et al 1997;Ferrante et al 2002;Rosenfeldt et al 2003Rosenfeldt et al , 2007Hyson et al 2010). Furthermore, several investigations suggest that supplementation of CoQ could have effects similar to caloric restriction or antioxidant-rich foods.…”

mentioning

confidence: 99%

Coenzyme Q10 supplementation reverses age-related impairments in spatial learning and lowers protein oxidation

Shetty

Forster

Sumien

2012

AGE

View full text Add to dashboard Cite

Coenzyme Q10 (CoQ) is widely available as a dietary supplement and remains under consideration as a treatment for age-associated neurodegenerative conditions. However, no studies have determined if supplementation, initiated relatively late in life, could have beneficial effects on mild functional impairments associated with normal brain aging. Accordingly, the current study assessed the effect of CoQ intake in older mice for which cognitive and psychomotor impairments were already evident. Separate groups of young (3.5 months) and relatively old mice (17.5 months) were fed a control diet or a diet supplemented with low (0.72 mg/g) or high (2.81 mg/g) concentrations of CoQ for 15 weeks. After 6 weeks, the mice were given tests for spatial learning (Morris water maze), spontaneous locomotor activity, motor coordination, and startle reflex. Age-related impairments in cognitive and psychomotor functions were evident in the 17.5-month-old mice fed the control diet, and the low-CoQ diet failed to affect any aspect of the impaired performance. However, in the Morris water maze test, old mice on the high-CoQ diet swam to the safe platform with greater efficiency than the mice on the control diet. The old mice supplemented with the highCoQ diet did not show improvement when spatial performance was measured using probe trials and failed to show improvement in other tests of behavioral performance. Protein oxidative damage was decreased in the mitochondria from the heart, liver, and skeletal muscle of the high-CoQ-supplemented mice and, to some extent, in the brain mitochondria. Contrasting with the deleterious effect of long-term CoQ supplementation initiated during young adulthood previously published, this study suggests that CoQ improves spatial learning and attenuates oxidative damage when administered in relatively high doses and delayed until early senescence, after agerelated declines have occurred. Thus, in individuals with age-associated symptoms of cognitive decline, highCoQ intake may be beneficial.

show abstract

mentioning

confidence: 99%

Coenzyme Q10 supplementation reverses age-related impairments in spatial learning and lowers protein oxidation

Shetty

Forster

Sumien

2012

AGE

View full text Add to dashboard Cite

show abstract

“…It is therefore conceivable that CoQ10 depletion, which has been found in the myocardium from patients with heart failure, 23) may contribute to the deterioration of functional capacity of failing hearts. Several studies 24,25) showed improvements in symptoms, quality of life, left ventricular function, and the prognosis of patients with heart failure after supplementation with CoQ10, while other studies 26,27) failed to demonstrate an improvement. Unfortunately, we did not evaluate the effect of CoQ10 supplementation on BNP levels in the present study.…”

Section: Discussionmentioning

confidence: 99%

Atorvastatin-Induced Changes in Plasma Coenzyme Q10 and Brain Natriuretic Peptide in Patients With Coronary Artery Disease

et al. 2008

View full text Add to dashboard Cite

SUMMARYThe beneficial effects of statins in patients with coronary artery disease (CAD) may be balanced by concerns that statins can depress production of ubiquinone (CoQ10), which serves as a component of mitochondrial energy production and an antioxidant. Accordingly, the effects of atorvastatin (ATO)-induced changes in plasma CoQ10 on BNP and oxidative stress were investigated. In 29 patients with CAD, the plasma levels of CoQ10 and BNP and urinary excretion of 8-iso-prostaglandin F2α (8-iso-PGF) were determined before and after 3-month treatment with ATO. Ten patients had received pravastatin and 10 patients fluvastatin, while 9 patients had not received any statin before ATO. There was a linear correlation between ATO-induced changes in total cholesterol and CoQ10 (r = 0.632, P < 0.01), and an inverse correlation between ATO-induced changes in CoQ10 and BNP (r = -0.497, P < 0.01). There was no significant correlation between ATO-induced changes in CoQ10 and 8-iso-PGF. Multivariate analysis revealed that ATO-induced decreases in plasma CoQ10 were significantly associated with increasing BNP levels. In conclusion, long-term treatment with ATO might increase plasma levels of BNP in patients with CAD when it is accompanied by a greater reduction in plasma CoQ10. However, ATO-induced decreases in CoQ10 might not increase oxidative stress. (Int Heart J 2008; 49: 423-433)

show abstract

“…Soja i Mortensen [36] dokonali przeglądu 8 podwójnie zaślepionych badań z grupą kontrolną [38][39][40][41][42][43][44][45] i po zastosowaniu suplementacji CoQ 10 odnotowali istotną poprawę w zakresie objętości sobie już wiele dekad. Niektóre wyniki badań wykazały, że suplementacja CoQ 10 przez relatywnie krótki czas może poprawić funkcję skurczową i zmniejszać wymiary komory, podczas gdy inne nie udowodniły korzyści w porównaniu z placebo.…”

Section: Badania Interwencyjne Z Koenzymem Q 10unclassified

“…[3] dokonali przeglądu 12 badań: 10 z nich oceniało frakcję wyrzutową [38,[40][41][42][45][46][47][48][49][50], a 2 -rzut serca [44,46], z dawkowaniem CoQ 10 w zakresie od 60 do 200 mg/dziennie i okresem leczenia od 1 do 6 miesięcy (tab. 1).…”

Section: Jakie Są Konsekwencje Stosowaniaunclassified

Koenzym Q10 i zastoinowa niewydolność serca: zmieniające się dowody naukowe

Florkowski

Molyneux²,

Young³

2015

Kardiol Pol

View full text Add to dashboard Cite

Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure

Cited by 150 publications

References 14 publications

Coenzyme Q10 supplementation reverses age-related impairments in spatial learning and lowers protein oxidation

Coenzyme Q10 supplementation reverses age-related impairments in spatial learning and lowers protein oxidation

Atorvastatin-Induced Changes in Plasma Coenzyme Q10 and Brain Natriuretic Peptide in Patients With Coronary Artery Disease

Koenzym Q10 i zastoinowa niewydolność serca: zmieniające się dowody naukowe

Contact Info

Product

Resources

About